WILD-TYPE

作品数：121被引量：282H指数：8
导出分析报告
相关领域：医药卫生生物学更多>>
相关作者：牟珍珍姚庆宇王丽杰袁茵李静云更多>>
相关机构：北京大学第四军医大学西京医院四川省肿瘤医院中国医学科学院更多>>
相关期刊：更多>>
相关基金：国家自然科学基金国家重点基础研究发展计划广东省自然科学基金天津市自然科学基金更多>>
-
在结果中检索

检索结果分析

结果分析中...
选择条件：
  • 期刊=Bioactive Materialsx
共 条 记 录，以下是1-2
全选清除导出
参考文献引证文献引用追踪
视图：
排序：
Carrier-free nanoprodrug for p53-mutated tumor therapy via concurrent delivery of zinc-manganese dual ions and ROS被引量：2
《Bioactive Materials》2023年第2期404-417,共14页Jinping Wang Chang Qu Xinyue Shao Guoqiang Song Jingyu Sun Donghong Shi Ran Jia Hailong An Hongjun Wang 
supported by the NIAMS award number 1R01AR067859;National Natural Science Foundation of China(82102208,81830061);Program for Excellent Innovative Talents in Universities of Hebei Province(BJ2021019);Natural Science Foundation of Hebei Province(H2021202002,H2020202005);the Natural Science Foundation of Tianjin(19JCYBJC28300).
Human cancers typically express a high level of tumor-promoting mutant p53 protein(Mutp53)with a minimal level of tumor-suppressing wild-type p53 protein(WTp53).In this regard,inducing Mutp53 degradation while activat...
关键词：p53-mutated tumor therapy Wild-type p53 protein Carrier-free nanoprodrug Mn-ZnO_(2)nanoparticle Reactive oxygen species 
A multifunctional nanotheranostic agent potentiates erlotinib to EGFR wild-type non-small cell lung cancer
《Bioactive Materials》2022年第7期312-323,共12页Duo Wang Jun Zhou Weimin Fang Cuiqing Huang Zerong Chen Meng Fan Ming-Rong Zhang Zeyu Xiao Kuan Hu Liangping Luo 
This study was supported partly by grants from the Natural Science Foundation of China(81771973,81971672 and 82102005);Key Program of the Natural Science Foundation of Guangdong Province(2018B0303110011);Guangzhou Key Laboratory of Molecular and Functional Imaging for Clinical Translation(201905010003);Fundamental Research Funds for the Central Universities(21620308 and 21620101);JSPS KAKENHI grant Nos.21H02873,21K07659,and 20H03635;the AMED Moonshot Research and Development Program(Grant No 21zf0127003h001).
Epidermal growth factor receptor(EGFR)tyrosine kinase inhibitors(TKI),such as Erlotinib,have demonstrated remarkable efficacy in the treatment of non-small cell lung cancer(NSCLC)patients with mutated EGFR.However,the...
关键词：Non-small cell lung cancer EGFR wild-Type Superparamagnetic iron oxide ERLOTINIB BEVACIZUMAB Tumour vascular normalization 
全选清除导出
共1页<1>
检索报告 对象比较 聚类工具 使用帮助 返回顶部